Global Whole Genome Amplification Market
Global Whole Genome Amplification Market

Whole Genome Amplification Comprehensive Study by Type (Single Cell WGA Kit, Complete WGA Kit, WGA Reamplification Kit, WGA and Chip DNA Kit, Others), Application (Drug Discovery and Development, Disease Diagnosis, Agriculture and Veterinary, Research, Forensics, Others), End User (Pharma and Biotech Companies, Hospitals and Clinics) Players and Region - Global Market Outlook to 2026

Whole Genome Amplification Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Aug 2021 Edition 204 Pages 217 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Whole Genome Amplification Market Overview:
WGA stands for whole genome amplification, which is a technique for amplifying the complete DNA from a tiny sample of genomic DNA. WGA is gaining popularity since it aids in increasing the number of restricted DNA samples. This method is used to examine any gene in any organism using a restricted sample that has been kept. This application is widely used in a wide range of applications, including genetic disease research and forensics, among others. The polymerase chain reaction is used to enzymatically copy DNA from a genome sample in the whole genome amplification method.

Growth Drivers
  • Increasing adoption of whole genome amplification (WGA) for the examination of sequence
  • Rising incidence of cancer, cardiovascular ailments, and heart disease

Roadblocks
  • Lack of trust in the process

Opportunities
  • Development of advanced devices and kits
  • Introduction of novel techniques


Competitive Landscape:
The companies are determining the industry in new geographical areas by adopting various strategic growth areas such as mergers & acquisitions, expansions, investments, new product launches, and others. The market key players are exploring new areas through growths and achievements across the globe to benefit from competitive advantage through combined synergies.
Some of the key players profiled in the report are Merck KGaA (Germany), QIAGEN (Germany), GENERAL ELECTRIC COMPANY (United States), LGC Limited (United Kingdom), Illumina, Inc. (United States), Thermo Fisher Scientific, Inc. (United States), Eurofins Scientific (Luxembourg), Agilent Technologies, Inc. (United States), Oxford Nanopore Technologies (United Kingdom), F. Hoffmann-La Roche Ltd (Switzerland) and Bio-Rad Laboratories, Inc. (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Whole Genome Amplification market by 2026. Considering Market by End User, the sub-segment i.e. Pharma and Biotech Companies will boost the Whole Genome Amplification market.

In October 2020, BioSkryb launched its new ResolveDNATM kits incorporated with primary template-directed amplification (PTA) technology, to accurately and uniformly amplify the genomes of single cells.

What Can be Explored with the Whole Genome Amplification Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Whole Genome Amplification Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Whole Genome Amplification
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Whole Genome Amplification market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Whole Genome Amplification market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Whole Genome Amplification Provider, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Frequently Asked Questions (FAQ):

1. What is the growth rate predicted for the Global Whole Genome Amplification Market?
The Whole Genome Amplification market is expected to see a CAGR of % during projected year 2020 to 2026.

2. Who are the top performing companies in Whole Genome Amplification Market?
Top performing companies in the Global Whole Genome Amplification market are Merck KGaA (Germany), QIAGEN (Germany), GENERAL ELECTRIC COMPANY (United States), LGC Limited (United Kingdom), Illumina, Inc. (United States), Thermo Fisher Scientific, Inc. (United States), Eurofins Scientific (Luxembourg), Agilent Technologies, Inc. (United States), Oxford Nanopore Technologies (United Kingdom), F. Hoffmann-La Roche Ltd (Switzerland) and Bio-Rad Laboratories, Inc. (United States), to name a few.

3. What trending factors would impact Whole Genome Amplification Market growth most?
"Increasing innovation to increase the reliability of the wide range of whole genome amplification kits" is seen as one of major influencing trends for Whole Genome Amplification Market during projected period 2020-2026.

Report Objectives / Segmentation Covered
By Type
  • Single Cell WGA Kit
  • Complete WGA Kit
  • WGA Reamplification Kit
  • WGA and Chip DNA Kit
  • Others
By Application
  • Drug Discovery and Development
  • Disease Diagnosis
  • Agriculture and Veterinary
  • Research
  • Forensics
  • Others
By End User
  • Pharma and Biotech Companies
  • Hospitals and Clinics

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing adoption of whole genome amplification (WGA) for the examination of sequence
      • 3.2.2. Rising incidence of cancer, cardiovascular ailments, and heart disease
    • 3.3. Market Trends
      • 3.3.1. Increasing innovation to increase the reliability of the wide range of whole genome amplification kits
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Whole Genome Amplification, by Type, Application, End User and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Whole Genome Amplification (Value)
      • 5.2.1. Global Whole Genome Amplification by: Type (Value)
        • 5.2.1.1. Single Cell WGA Kit
        • 5.2.1.2. Complete WGA Kit
        • 5.2.1.3. WGA Reamplification Kit
        • 5.2.1.4. WGA and Chip DNA Kit
        • 5.2.1.5. Others
      • 5.2.2. Global Whole Genome Amplification by: Application (Value)
        • 5.2.2.1. Drug Discovery and Development
        • 5.2.2.2. Disease Diagnosis
        • 5.2.2.3. Agriculture and Veterinary
        • 5.2.2.4. Research
        • 5.2.2.5. Forensics
        • 5.2.2.6. Others
      • 5.2.3. Global Whole Genome Amplification by: End User (Value)
        • 5.2.3.1. Pharma and Biotech Companies
        • 5.2.3.2. Hospitals and Clinics
      • 5.2.4. Global Whole Genome Amplification Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Whole Genome Amplification (Price)
      • 5.3.1. Global Whole Genome Amplification by: Type (Price)
  • 6. Whole Genome Amplification: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck KGaA (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. QIAGEN (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GENERAL ELECTRIC COMPANY (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. LGC Limited (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Illumina, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Thermo Fisher Scientific, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Eurofins Scientific (Luxembourg)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Agilent Technologies, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Oxford Nanopore Technologies (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Bio-Rad Laboratories, Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Whole Genome Amplification Sale, by Type, Application, End User and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Whole Genome Amplification (Value)
      • 7.2.1. Global Whole Genome Amplification by: Type (Value)
        • 7.2.1.1. Single Cell WGA Kit
        • 7.2.1.2. Complete WGA Kit
        • 7.2.1.3. WGA Reamplification Kit
        • 7.2.1.4. WGA and Chip DNA Kit
        • 7.2.1.5. Others
      • 7.2.2. Global Whole Genome Amplification by: Application (Value)
        • 7.2.2.1. Drug Discovery and Development
        • 7.2.2.2. Disease Diagnosis
        • 7.2.2.3. Agriculture and Veterinary
        • 7.2.2.4. Research
        • 7.2.2.5. Forensics
        • 7.2.2.6. Others
      • 7.2.3. Global Whole Genome Amplification by: End User (Value)
        • 7.2.3.1. Pharma and Biotech Companies
        • 7.2.3.2. Hospitals and Clinics
      • 7.2.4. Global Whole Genome Amplification Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Whole Genome Amplification (Price)
      • 7.3.1. Global Whole Genome Amplification by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Whole Genome Amplification: by Type(USD Million)
  • Table 2. Whole Genome Amplification Single Cell WGA Kit , by Region USD Million (2015-2020)
  • Table 3. Whole Genome Amplification Complete WGA Kit , by Region USD Million (2015-2020)
  • Table 4. Whole Genome Amplification WGA Reamplification Kit , by Region USD Million (2015-2020)
  • Table 5. Whole Genome Amplification WGA and Chip DNA Kit , by Region USD Million (2015-2020)
  • Table 6. Whole Genome Amplification Others , by Region USD Million (2015-2020)
  • Table 7. Whole Genome Amplification: by Application(USD Million)
  • Table 8. Whole Genome Amplification Drug Discovery and Development , by Region USD Million (2015-2020)
  • Table 9. Whole Genome Amplification Disease Diagnosis , by Region USD Million (2015-2020)
  • Table 10. Whole Genome Amplification Agriculture and Veterinary , by Region USD Million (2015-2020)
  • Table 11. Whole Genome Amplification Research , by Region USD Million (2015-2020)
  • Table 12. Whole Genome Amplification Forensics , by Region USD Million (2015-2020)
  • Table 13. Whole Genome Amplification Others , by Region USD Million (2015-2020)
  • Table 14. Whole Genome Amplification: by End User(USD Million)
  • Table 15. Whole Genome Amplification Pharma and Biotech Companies , by Region USD Million (2015-2020)
  • Table 16. Whole Genome Amplification Hospitals and Clinics , by Region USD Million (2015-2020)
  • Table 17. South America Whole Genome Amplification, by Country USD Million (2015-2020)
  • Table 18. South America Whole Genome Amplification, by Type USD Million (2015-2020)
  • Table 19. South America Whole Genome Amplification, by Application USD Million (2015-2020)
  • Table 20. South America Whole Genome Amplification, by End User USD Million (2015-2020)
  • Table 21. Brazil Whole Genome Amplification, by Type USD Million (2015-2020)
  • Table 22. Brazil Whole Genome Amplification, by Application USD Million (2015-2020)
  • Table 23. Brazil Whole Genome Amplification, by End User USD Million (2015-2020)
  • Table 24. Argentina Whole Genome Amplification, by Type USD Million (2015-2020)
  • Table 25. Argentina Whole Genome Amplification, by Application USD Million (2015-2020)
  • Table 26. Argentina Whole Genome Amplification, by End User USD Million (2015-2020)
  • Table 27. Rest of South America Whole Genome Amplification, by Type USD Million (2015-2020)
  • Table 28. Rest of South America Whole Genome Amplification, by Application USD Million (2015-2020)
  • Table 29. Rest of South America Whole Genome Amplification, by End User USD Million (2015-2020)
  • Table 30. Asia Pacific Whole Genome Amplification, by Country USD Million (2015-2020)
  • Table 31. Asia Pacific Whole Genome Amplification, by Type USD Million (2015-2020)
  • Table 32. Asia Pacific Whole Genome Amplification, by Application USD Million (2015-2020)
  • Table 33. Asia Pacific Whole Genome Amplification, by End User USD Million (2015-2020)
  • Table 34. China Whole Genome Amplification, by Type USD Million (2015-2020)
  • Table 35. China Whole Genome Amplification, by Application USD Million (2015-2020)
  • Table 36. China Whole Genome Amplification, by End User USD Million (2015-2020)
  • Table 37. Japan Whole Genome Amplification, by Type USD Million (2015-2020)
  • Table 38. Japan Whole Genome Amplification, by Application USD Million (2015-2020)
  • Table 39. Japan Whole Genome Amplification, by End User USD Million (2015-2020)
  • Table 40. India Whole Genome Amplification, by Type USD Million (2015-2020)
  • Table 41. India Whole Genome Amplification, by Application USD Million (2015-2020)
  • Table 42. India Whole Genome Amplification, by End User USD Million (2015-2020)
  • Table 43. South Korea Whole Genome Amplification, by Type USD Million (2015-2020)
  • Table 44. South Korea Whole Genome Amplification, by Application USD Million (2015-2020)
  • Table 45. South Korea Whole Genome Amplification, by End User USD Million (2015-2020)
  • Table 46. Taiwan Whole Genome Amplification, by Type USD Million (2015-2020)
  • Table 47. Taiwan Whole Genome Amplification, by Application USD Million (2015-2020)
  • Table 48. Taiwan Whole Genome Amplification, by End User USD Million (2015-2020)
  • Table 49. Australia Whole Genome Amplification, by Type USD Million (2015-2020)
  • Table 50. Australia Whole Genome Amplification, by Application USD Million (2015-2020)
  • Table 51. Australia Whole Genome Amplification, by End User USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific Whole Genome Amplification, by Type USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific Whole Genome Amplification, by Application USD Million (2015-2020)
  • Table 54. Rest of Asia-Pacific Whole Genome Amplification, by End User USD Million (2015-2020)
  • Table 55. Europe Whole Genome Amplification, by Country USD Million (2015-2020)
  • Table 56. Europe Whole Genome Amplification, by Type USD Million (2015-2020)
  • Table 57. Europe Whole Genome Amplification, by Application USD Million (2015-2020)
  • Table 58. Europe Whole Genome Amplification, by End User USD Million (2015-2020)
  • Table 59. Germany Whole Genome Amplification, by Type USD Million (2015-2020)
  • Table 60. Germany Whole Genome Amplification, by Application USD Million (2015-2020)
  • Table 61. Germany Whole Genome Amplification, by End User USD Million (2015-2020)
  • Table 62. France Whole Genome Amplification, by Type USD Million (2015-2020)
  • Table 63. France Whole Genome Amplification, by Application USD Million (2015-2020)
  • Table 64. France Whole Genome Amplification, by End User USD Million (2015-2020)
  • Table 65. Italy Whole Genome Amplification, by Type USD Million (2015-2020)
  • Table 66. Italy Whole Genome Amplification, by Application USD Million (2015-2020)
  • Table 67. Italy Whole Genome Amplification, by End User USD Million (2015-2020)
  • Table 68. United Kingdom Whole Genome Amplification, by Type USD Million (2015-2020)
  • Table 69. United Kingdom Whole Genome Amplification, by Application USD Million (2015-2020)
  • Table 70. United Kingdom Whole Genome Amplification, by End User USD Million (2015-2020)
  • Table 71. Netherlands Whole Genome Amplification, by Type USD Million (2015-2020)
  • Table 72. Netherlands Whole Genome Amplification, by Application USD Million (2015-2020)
  • Table 73. Netherlands Whole Genome Amplification, by End User USD Million (2015-2020)
  • Table 74. Rest of Europe Whole Genome Amplification, by Type USD Million (2015-2020)
  • Table 75. Rest of Europe Whole Genome Amplification, by Application USD Million (2015-2020)
  • Table 76. Rest of Europe Whole Genome Amplification, by End User USD Million (2015-2020)
  • Table 77. MEA Whole Genome Amplification, by Country USD Million (2015-2020)
  • Table 78. MEA Whole Genome Amplification, by Type USD Million (2015-2020)
  • Table 79. MEA Whole Genome Amplification, by Application USD Million (2015-2020)
  • Table 80. MEA Whole Genome Amplification, by End User USD Million (2015-2020)
  • Table 81. Middle East Whole Genome Amplification, by Type USD Million (2015-2020)
  • Table 82. Middle East Whole Genome Amplification, by Application USD Million (2015-2020)
  • Table 83. Middle East Whole Genome Amplification, by End User USD Million (2015-2020)
  • Table 84. Africa Whole Genome Amplification, by Type USD Million (2015-2020)
  • Table 85. Africa Whole Genome Amplification, by Application USD Million (2015-2020)
  • Table 86. Africa Whole Genome Amplification, by End User USD Million (2015-2020)
  • Table 87. North America Whole Genome Amplification, by Country USD Million (2015-2020)
  • Table 88. North America Whole Genome Amplification, by Type USD Million (2015-2020)
  • Table 89. North America Whole Genome Amplification, by Application USD Million (2015-2020)
  • Table 90. North America Whole Genome Amplification, by End User USD Million (2015-2020)
  • Table 91. United States Whole Genome Amplification, by Type USD Million (2015-2020)
  • Table 92. United States Whole Genome Amplification, by Application USD Million (2015-2020)
  • Table 93. United States Whole Genome Amplification, by End User USD Million (2015-2020)
  • Table 94. Canada Whole Genome Amplification, by Type USD Million (2015-2020)
  • Table 95. Canada Whole Genome Amplification, by Application USD Million (2015-2020)
  • Table 96. Canada Whole Genome Amplification, by End User USD Million (2015-2020)
  • Table 97. Mexico Whole Genome Amplification, by Type USD Million (2015-2020)
  • Table 98. Mexico Whole Genome Amplification, by Application USD Million (2015-2020)
  • Table 99. Mexico Whole Genome Amplification, by End User USD Million (2015-2020)
  • Table 100. Whole Genome Amplification: by Type(USD/Units)
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Whole Genome Amplification: by Type(USD Million)
  • Table 113. Whole Genome Amplification Single Cell WGA Kit , by Region USD Million (2021-2026)
  • Table 114. Whole Genome Amplification Complete WGA Kit , by Region USD Million (2021-2026)
  • Table 115. Whole Genome Amplification WGA Reamplification Kit , by Region USD Million (2021-2026)
  • Table 116. Whole Genome Amplification WGA and Chip DNA Kit , by Region USD Million (2021-2026)
  • Table 117. Whole Genome Amplification Others , by Region USD Million (2021-2026)
  • Table 118. Whole Genome Amplification: by Application(USD Million)
  • Table 119. Whole Genome Amplification Drug Discovery and Development , by Region USD Million (2021-2026)
  • Table 120. Whole Genome Amplification Disease Diagnosis , by Region USD Million (2021-2026)
  • Table 121. Whole Genome Amplification Agriculture and Veterinary , by Region USD Million (2021-2026)
  • Table 122. Whole Genome Amplification Research , by Region USD Million (2021-2026)
  • Table 123. Whole Genome Amplification Forensics , by Region USD Million (2021-2026)
  • Table 124. Whole Genome Amplification Others , by Region USD Million (2021-2026)
  • Table 125. Whole Genome Amplification: by End User(USD Million)
  • Table 126. Whole Genome Amplification Pharma and Biotech Companies , by Region USD Million (2021-2026)
  • Table 127. Whole Genome Amplification Hospitals and Clinics , by Region USD Million (2021-2026)
  • Table 128. South America Whole Genome Amplification, by Country USD Million (2021-2026)
  • Table 129. South America Whole Genome Amplification, by Type USD Million (2021-2026)
  • Table 130. South America Whole Genome Amplification, by Application USD Million (2021-2026)
  • Table 131. South America Whole Genome Amplification, by End User USD Million (2021-2026)
  • Table 132. Brazil Whole Genome Amplification, by Type USD Million (2021-2026)
  • Table 133. Brazil Whole Genome Amplification, by Application USD Million (2021-2026)
  • Table 134. Brazil Whole Genome Amplification, by End User USD Million (2021-2026)
  • Table 135. Argentina Whole Genome Amplification, by Type USD Million (2021-2026)
  • Table 136. Argentina Whole Genome Amplification, by Application USD Million (2021-2026)
  • Table 137. Argentina Whole Genome Amplification, by End User USD Million (2021-2026)
  • Table 138. Rest of South America Whole Genome Amplification, by Type USD Million (2021-2026)
  • Table 139. Rest of South America Whole Genome Amplification, by Application USD Million (2021-2026)
  • Table 140. Rest of South America Whole Genome Amplification, by End User USD Million (2021-2026)
  • Table 141. Asia Pacific Whole Genome Amplification, by Country USD Million (2021-2026)
  • Table 142. Asia Pacific Whole Genome Amplification, by Type USD Million (2021-2026)
  • Table 143. Asia Pacific Whole Genome Amplification, by Application USD Million (2021-2026)
  • Table 144. Asia Pacific Whole Genome Amplification, by End User USD Million (2021-2026)
  • Table 145. China Whole Genome Amplification, by Type USD Million (2021-2026)
  • Table 146. China Whole Genome Amplification, by Application USD Million (2021-2026)
  • Table 147. China Whole Genome Amplification, by End User USD Million (2021-2026)
  • Table 148. Japan Whole Genome Amplification, by Type USD Million (2021-2026)
  • Table 149. Japan Whole Genome Amplification, by Application USD Million (2021-2026)
  • Table 150. Japan Whole Genome Amplification, by End User USD Million (2021-2026)
  • Table 151. India Whole Genome Amplification, by Type USD Million (2021-2026)
  • Table 152. India Whole Genome Amplification, by Application USD Million (2021-2026)
  • Table 153. India Whole Genome Amplification, by End User USD Million (2021-2026)
  • Table 154. South Korea Whole Genome Amplification, by Type USD Million (2021-2026)
  • Table 155. South Korea Whole Genome Amplification, by Application USD Million (2021-2026)
  • Table 156. South Korea Whole Genome Amplification, by End User USD Million (2021-2026)
  • Table 157. Taiwan Whole Genome Amplification, by Type USD Million (2021-2026)
  • Table 158. Taiwan Whole Genome Amplification, by Application USD Million (2021-2026)
  • Table 159. Taiwan Whole Genome Amplification, by End User USD Million (2021-2026)
  • Table 160. Australia Whole Genome Amplification, by Type USD Million (2021-2026)
  • Table 161. Australia Whole Genome Amplification, by Application USD Million (2021-2026)
  • Table 162. Australia Whole Genome Amplification, by End User USD Million (2021-2026)
  • Table 163. Rest of Asia-Pacific Whole Genome Amplification, by Type USD Million (2021-2026)
  • Table 164. Rest of Asia-Pacific Whole Genome Amplification, by Application USD Million (2021-2026)
  • Table 165. Rest of Asia-Pacific Whole Genome Amplification, by End User USD Million (2021-2026)
  • Table 166. Europe Whole Genome Amplification, by Country USD Million (2021-2026)
  • Table 167. Europe Whole Genome Amplification, by Type USD Million (2021-2026)
  • Table 168. Europe Whole Genome Amplification, by Application USD Million (2021-2026)
  • Table 169. Europe Whole Genome Amplification, by End User USD Million (2021-2026)
  • Table 170. Germany Whole Genome Amplification, by Type USD Million (2021-2026)
  • Table 171. Germany Whole Genome Amplification, by Application USD Million (2021-2026)
  • Table 172. Germany Whole Genome Amplification, by End User USD Million (2021-2026)
  • Table 173. France Whole Genome Amplification, by Type USD Million (2021-2026)
  • Table 174. France Whole Genome Amplification, by Application USD Million (2021-2026)
  • Table 175. France Whole Genome Amplification, by End User USD Million (2021-2026)
  • Table 176. Italy Whole Genome Amplification, by Type USD Million (2021-2026)
  • Table 177. Italy Whole Genome Amplification, by Application USD Million (2021-2026)
  • Table 178. Italy Whole Genome Amplification, by End User USD Million (2021-2026)
  • Table 179. United Kingdom Whole Genome Amplification, by Type USD Million (2021-2026)
  • Table 180. United Kingdom Whole Genome Amplification, by Application USD Million (2021-2026)
  • Table 181. United Kingdom Whole Genome Amplification, by End User USD Million (2021-2026)
  • Table 182. Netherlands Whole Genome Amplification, by Type USD Million (2021-2026)
  • Table 183. Netherlands Whole Genome Amplification, by Application USD Million (2021-2026)
  • Table 184. Netherlands Whole Genome Amplification, by End User USD Million (2021-2026)
  • Table 185. Rest of Europe Whole Genome Amplification, by Type USD Million (2021-2026)
  • Table 186. Rest of Europe Whole Genome Amplification, by Application USD Million (2021-2026)
  • Table 187. Rest of Europe Whole Genome Amplification, by End User USD Million (2021-2026)
  • Table 188. MEA Whole Genome Amplification, by Country USD Million (2021-2026)
  • Table 189. MEA Whole Genome Amplification, by Type USD Million (2021-2026)
  • Table 190. MEA Whole Genome Amplification, by Application USD Million (2021-2026)
  • Table 191. MEA Whole Genome Amplification, by End User USD Million (2021-2026)
  • Table 192. Middle East Whole Genome Amplification, by Type USD Million (2021-2026)
  • Table 193. Middle East Whole Genome Amplification, by Application USD Million (2021-2026)
  • Table 194. Middle East Whole Genome Amplification, by End User USD Million (2021-2026)
  • Table 195. Africa Whole Genome Amplification, by Type USD Million (2021-2026)
  • Table 196. Africa Whole Genome Amplification, by Application USD Million (2021-2026)
  • Table 197. Africa Whole Genome Amplification, by End User USD Million (2021-2026)
  • Table 198. North America Whole Genome Amplification, by Country USD Million (2021-2026)
  • Table 199. North America Whole Genome Amplification, by Type USD Million (2021-2026)
  • Table 200. North America Whole Genome Amplification, by Application USD Million (2021-2026)
  • Table 201. North America Whole Genome Amplification, by End User USD Million (2021-2026)
  • Table 202. United States Whole Genome Amplification, by Type USD Million (2021-2026)
  • Table 203. United States Whole Genome Amplification, by Application USD Million (2021-2026)
  • Table 204. United States Whole Genome Amplification, by End User USD Million (2021-2026)
  • Table 205. Canada Whole Genome Amplification, by Type USD Million (2021-2026)
  • Table 206. Canada Whole Genome Amplification, by Application USD Million (2021-2026)
  • Table 207. Canada Whole Genome Amplification, by End User USD Million (2021-2026)
  • Table 208. Mexico Whole Genome Amplification, by Type USD Million (2021-2026)
  • Table 209. Mexico Whole Genome Amplification, by Application USD Million (2021-2026)
  • Table 210. Mexico Whole Genome Amplification, by End User USD Million (2021-2026)
  • Table 211. Whole Genome Amplification: by Type(USD/Units)
  • Table 212. Research Programs/Design for This Report
  • Table 213. Key Data Information from Secondary Sources
  • Table 214. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Whole Genome Amplification: by Type USD Million (2015-2020)
  • Figure 5. Global Whole Genome Amplification: by Application USD Million (2015-2020)
  • Figure 6. Global Whole Genome Amplification: by End User USD Million (2015-2020)
  • Figure 7. South America Whole Genome Amplification Share (%), by Country
  • Figure 8. Asia Pacific Whole Genome Amplification Share (%), by Country
  • Figure 9. Europe Whole Genome Amplification Share (%), by Country
  • Figure 10. MEA Whole Genome Amplification Share (%), by Country
  • Figure 11. North America Whole Genome Amplification Share (%), by Country
  • Figure 12. Global Whole Genome Amplification: by Type USD/Units (2015-2020)
  • Figure 13. Global Whole Genome Amplification share by Players 2020 (%)
  • Figure 14. Global Whole Genome Amplification share by Players (Top 3) 2020(%)
  • Figure 15. Global Whole Genome Amplification share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 18. Merck KGaA (Germany) Revenue: by Geography 2020
  • Figure 19. QIAGEN (Germany) Revenue, Net Income and Gross profit
  • Figure 20. QIAGEN (Germany) Revenue: by Geography 2020
  • Figure 21. GENERAL ELECTRIC COMPANY (United States) Revenue, Net Income and Gross profit
  • Figure 22. GENERAL ELECTRIC COMPANY (United States) Revenue: by Geography 2020
  • Figure 23. LGC Limited (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 24. LGC Limited (United Kingdom) Revenue: by Geography 2020
  • Figure 25. Illumina, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Illumina, Inc. (United States) Revenue: by Geography 2020
  • Figure 27. Thermo Fisher Scientific, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Thermo Fisher Scientific, Inc. (United States) Revenue: by Geography 2020
  • Figure 29. Eurofins Scientific (Luxembourg) Revenue, Net Income and Gross profit
  • Figure 30. Eurofins Scientific (Luxembourg) Revenue: by Geography 2020
  • Figure 31. Agilent Technologies, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Agilent Technologies, Inc. (United States) Revenue: by Geography 2020
  • Figure 33. Oxford Nanopore Technologies (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. Oxford Nanopore Technologies (United Kingdom) Revenue: by Geography 2020
  • Figure 35. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 36. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2020
  • Figure 37. Bio-Rad Laboratories, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Bio-Rad Laboratories, Inc. (United States) Revenue: by Geography 2020
  • Figure 39. Global Whole Genome Amplification: by Type USD Million (2021-2026)
  • Figure 40. Global Whole Genome Amplification: by Application USD Million (2021-2026)
  • Figure 41. Global Whole Genome Amplification: by End User USD Million (2021-2026)
  • Figure 42. South America Whole Genome Amplification Share (%), by Country
  • Figure 43. Asia Pacific Whole Genome Amplification Share (%), by Country
  • Figure 44. Europe Whole Genome Amplification Share (%), by Country
  • Figure 45. MEA Whole Genome Amplification Share (%), by Country
  • Figure 46. North America Whole Genome Amplification Share (%), by Country
  • Figure 47. Global Whole Genome Amplification: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • Merck KGaA (Germany)
  • QIAGEN (Germany)
  • GENERAL ELECTRIC COMPANY (United States)
  • LGC Limited (United Kingdom)
  • Illumina, Inc. (United States)
  • Thermo Fisher Scientific, Inc. (United States)
  • Eurofins Scientific (Luxembourg)
  • Agilent Technologies, Inc. (United States)
  • Oxford Nanopore Technologies (United Kingdom)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Bio-Rad Laboratories, Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation